NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients

Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients

27 August 2021 · Listed under COVID-19, Gene and Cell Therapy, Oxford Blood Group

The COVID-19 pandemic has led to understandable anxiety within the blood cancer community about how their illness may affect their ability to overcome COVID-19 infection.

Members of the Oxford Centre for Haematology have led a collaborative research project looking at the response of patients with chronic lymphocytic leukaemia (CLL) who were infected with COVID-19.

The results of the study, which was supported by the NIHR oxford BRC, have been reported in the journal Blood. 

CLL is a type of blood cancer where white blood cells called B lymphocytes grow out of control. The disease is typically slow to develop, showing few symptoms at the beginning. Around 4,000 people are diagnosed with CLL each year in the UK, more commonly among people over 60 years old, and there are a variety of treatments available, depending on the stage of disease progression.  

In the recent study, investigators from 45 centres selected 374 patients with CLL who were diagnosed with COVID-19 in two time periods: February-April 2020; and May 2020-January 2021.

Trends showed that CLL patients diagnosed with COVID-19 in spring 2020 experienced a high case fatality rate (31-33%). At this point the, the US authorities permitted the use of dexamethasone for COVID-19-infected patients requiring oxygen and a wider set of treatment guidelines were disseminated.

There followed an improvement in survival for patients infected with COVID-19 after May 2020, which was likely due to improvements in treatment. This trend in overall survival for CLL patients mirrored that observed in the general population.

Further analysis compared the effect of a range of treatments including dexamethasone, remdesivir, convalescent plasma, corticosteroids and hydroxychloroquine in the CLL COVID-19 patient group.

Researchers also analysed how long patients required intensive care treatment in hospital, how many needed oxygen, whether their BTKi cancer therapy was continued during COVID infection, and whether there was any correlation of the overall survival rate to age, gender or cumulative illness rating scale. 

A final question concerned the efficacy of COVID-19 vaccines to promote an immune response in CLL patients. Serology tests showed that 60% of CLL patients developed COVID-19 antibodies, although the response varied considerably. Ongoing research aims to understand the immune response to COVID-19 vaccination. 

“Since the beginning of the COVID-19 pandemic, medical staff have worked very hard to optimise treatment for patients, and it is gratifying to see the improvements in survival of CLL patients to COVID-19 infection” said Dr Toby Eyre, Consultant Haematologist at the Oxford University Hospitals NHS Foundation Trust, and the co-lead of the research project.

“The Oxford Centre for Haematology, with funding from the NIHR Oxford BRC, is in a strong position to coordinate both retrospective and clinical trials to add to the body of knowledge about how best to treat blood cancer patients during the COVID pandemic.”

Read the research paper. 

Find out more about the Oxford Centre for Haematology.

← New study launched to understand vaccine escape
Researchers develop algorithm to diagnose deep vein thrombosis →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre